Myelofibrosis treatment drugs

Myelofibrosis is a reactive and reversible process common to many malignant and benign bone marrow disorders. It can present de novo as primary myelofibrosis (PMF), or as secondary (reactive) myelofibrosis if caused by another disorder, drug treatment, or toxic agent.

The FDA has approved momelotinib (Ojjaara) for the treatment of adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, and anemia.

For the treatment of patients with myelofibrosis including primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia

Emerging drugs for the treatment of Myelofibrosis. Shreenivas A, Mascarenhas Drug Administration (FDA)-approved medicinal therapy for the treatment of MF.

On September 15, the U.S. Food and Drug Administration (FDA) approved momelotinib (Ojjaara) for the treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post polycythemia vera and post essential thrombocythemia), in adults with anemia.

GSK's Ojjaara (momelotinib), the first and only treatment for myelofibrosis patients with anemia regardless of prior myelofibrosis therapy

Description and Brand Names. Drug information provided by: Merative, Micromedex US Brand Name. Jakafi; Descriptions. Ruxolitinib is used to treat intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.

In 2024, the leading global drug class myelofibrosis market in 5EU was JAK Inhibitors. The key classes of drugs in the 5EU myelofibrosis market

Myelofibrosis is a chronic disease that requires medical intervention. No homeopathic or natural cures are proven for myelofibrosis treatments.